Vaccine market and production capabilities in the Americas
Open Access
- 13 April 2021
- journal article
- review article
- Published by Springer Nature in Tropical Diseases, Travel Medicine and Vaccines
- Vol. 7 (1) , 1-21
Abstract
In the Americas, The United States of America, Canada, Mexico, and Brazil are the top vaccine producers and the countries with the leading infrastructure for biological manufacturing. The North American countries have the most demanding legislation regulating and controlling these pharmaceuticals’ distribution and production. Some Latin American countries rank in the top 20 of worldwide vaccine manufacturers, with Cuba, Brazil, México and Colombia have a self-sufficient vaccine production of 72.7%, 54,2%; 25%; and 7.7%, respectively, of the national vaccine demand. On the other hand, the rest of Latin American countries cannot satisfy their demand for vaccines, and most of their efforts are associated with the distribution within their health systems rather than in transferring technology.Based on this literature review, the results suggest an increasing growth vaccine demand, not only for their growing populations and previously established demand but also for the recently exerted pressure due to the COVID-19 pandemic.Because the American continent has a marked inequality between the hegemonic producers of vaccines, the exporters, and those that depend heavily on importing these products, this could assert technological dependence in countries with rapid population growth and jeopardize the effectiveness of the two vaccination plans.Keywords
This publication has 34 references indexed in Scilit:
- The development of vaccines: how the past led to the futureNature Reviews Microbiology, 2011
- Elimination of Rubella and Congenital Rubella Syndrome in the AmericasThe Journal of Infectious Diseases, 2011
- WHO initiative to increase global and equitable access to influenza vaccine in the event of a pandemic: Supporting developing country production capacity through technology transferVaccine, 2011
- Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United StatesVaccine, 2010
- Mercado farmacéutico en México: tamaño, valor y concentraciónRevista Panamericana de Salud Pública, 2009
- The Impact Of Globalization On Vaccine Development And AvailabilityHealth Affairs, 2006
- Vaccines for preventing malaria (SPf66)Cochrane Database of Systematic Reviews, 2006
- Epidemiología de la hepatitis B en Chile y esquemas de vacunación en LatinoaméricaRevista chilena de infectología, 2002
- Coagulation factors and their inhibitorsCurrent Opinion in Structural Biology, 1994
- Study of the safety and immunogenicity of the synthetic malaria SPf66 vaccine in children aged 1–14 yearsVaccine, 1992